

Please be sure to complete the following:

Company name Protai * Website www.Protai.bio *

CEO name Eran Seger

Highlight the relevant session below -

1. Longevity - How to Complete the Centenarian Decathlon?
2. Do we Know Enough About the Brain to Treat Neurological Disorders?
3. Are Cancer Therapeutics Fulfilling the Promise?
4. Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?
5. AI Tapestry: Optimizing the Interaction of AI and Biopharma
6. Facts and Myths on Ex-Liver Drug Delivery and New Horizons to Cure Rare Disorders
7. [Who Owns Health Decisions? The Changing Dynamics of Patient-Physician Relationships in the Digital Health Revolution](#)
8. Robots Dancing with Humans in the Healthcare Systems and Homes
9. Are Medical Devices Still Relevant in the Context of New Biology?
10. Let Food be Thy Medicine and Medicine be Thy Food
11. How do we make Academic Translation Medicine replicable and relevant?
12. Bio Convergence: Everything That Rises Must Converge
13. High Pace Innovation in Dermatology & Medical Aesthetics
14. Navigating Global Collaborations in Times of Uncertainty: Can we turn challenges into growth opportunities?
15. Ophthalmology, from R&D to Commercialization

Title of the Presentation: Protai – Proteomics & AI discovery

Executive Summary

Protai is an AI drug discovery company, leveraging the power of Proteomic data to create better therapeutics. It's a tel aviv aviv backed by top tier bio and tech VCs, raised \$20M to date.

The single biggest challenge in drug approval is accurately predicting which patients will respond to a specific drug. The response rate barrier is the biggest cause for clinical trial failures, bringing a need for better predictive response biomarkers, using our proteomics platform.

While most precision oncology companies are focusing on Genomics, the Genome Layer has a predictive power only for a small portion of patients with druggable driver mutations. The real function is conducted by proteins and their interaction, which are the building blocks of life. Proteomic biomarkers have the potential to be broadly applicable for the vast majority of cancers, giving Protai a unique opportunity to help a larger piece of the patient scope.

To tackle this challenge, Protai has built a vertically integrated discovery platform, leveraging unique and proprietary clinical proteomics data from solid tumors. The data feeds our AI based prediction engine, to generate clinically meaningful predictions for cancer patients.

This unique platform enables both the creation of an internal innovative pipeline, starting in oncology, currently progressing several biomarker led therapeutic assets in the discovery stages, alongside assisting our biopharma partners to expedite their development. Generating First-in-class drugs on validated targets using novel proteomics biomarkers.